Stroke, TIA Quality of Care Varies Across Facilities
Care quality for patients with transient ischemic attack or minor stroke varies substantially across elements of care and facilities.
Care quality for patients with transient ischemic attack or minor stroke varies substantially across elements of care and facilities.
Pioglitazone is associated with greater benefit for those at higher risk for stroke or myocardial infarction after an ischemic attack or transient ischemic attack.
Risk of a second stroke or transient ischemic attack increases in stable survivors.
The American Heart Association and the American Stroke association report that only 3% of Americans who experience transient ischemic attack symptoms get medical attention.
Pioglitazone reduced the risk of acute coronary syndromes, including type 1 myocardial infarction.
The TARDIS trial aimed to assess whether 30 days of triple antiplatelet therapy was more effective in reducing recurrent stroke after previous transient ischemic attack or non-cardioembolic stroke than current guideline-based antiplatelet therapy.
Relative to tricyclic antidepressants, SSRIs were associated with an increased risk for intracranial hemorrhage.
Higher risk of cerebrovascular events was observed in chronic kidney disease, new-onset atrial fibrillation, and in procedures performed “within the first half of center experience.”
Mean HOMA-IR and fasting plasma glucose decreased in the pioglitazone group and increased in the placebo group after one year.
The most common sites for aneurysm were extracranial, renal and intracranial arteries, and the most common sites for dissection were extracranial carotid, vertebral, renal, and coronary arteries.